Stockscreener 앱 받기
2.67
2.69%
0.07
시간 외 거래:
2.67
전일 마감가:
$2.60
열려 있는:
$2.57
하루 거래량:
15,645
Relative Volume:
0.07
시가총액:
$2.35M
수익:
-
순이익/손실:
$-15.52M
주가수익비율:
-0.1437
EPS:
-18.58
순현금흐름:
$-16.61M
1주 성능:
-5.65%
1개월 성능:
-23.50%
6개월 성능:
-79.90%
1년 성능:
-93.56%
1일 변동 폭
$2.41
$2.67
1주일 범위
$2.41
$2.92
52주 변동 폭
$2.36
$60.80
Revelation Biosciences Inc Stock (REVB) Company Profile
명칭
Revelation Biosciences Inc
전화
650-800-3717
주소
4660 LAJOLLA VILLAGE DRIVE, SAN DIEGO
REVB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
REVB
Revelation Biosciences Inc
|
2.67 | 2.35M | 0 | -15.52M | -16.61M | -18.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Revelation Biosciences Inc 주식(REVB)의 최신 뉴스
Revelation Biosciences (REVB) to Release Earnings on Friday - Defense World
REVB stock touches 52-week low at $2.71 amid sharp annual decline - Investing.com
REVB stock touches 52-week low at $2.71 amid sharp annual decline By Investing.com - Investing.com South Africa
Revelation Biosciences: Gemini priming attenuates inflammatory response in PBMCs - TipRanks
Gemini Priming Attenuates Inflammation In Human Peripheral Blood Mononuclear Cells - Marketscreener.com
Gemini Priming Attenuates Inflammation in Human Peripheral Blood Mononuclear Cells - Business Wire
Pre-market Movers: REVB, QSI, EYEN, NAOV ... - RTTNews
Revelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference - Business Wire
Research Analysts Set Expectations for REVB FY2029 Earnings - Armenian Reporter
What is Roth Capital’s Estimate for REVB FY2029 Earnings? - Defense World
REVB: 2025 Is the Year for Measurable Progress - Research Tree
Revelation Biosciences Inc. (REVB) reports earnings - Quartz
Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024 - WICZ
Revelation Biosciences stock hits 52-week low at $3.26 By Investing.com - Investing.com South Africa
Revelation Biosciences stock hits 52-week low at $3.26 - Investing.com
Revelation Biosciences Doses First Patient In Prime Phase 1B Clinical Study Of Gemini In CKD Patients - Marketscreener.com
Revelation doses first patient in PRIME Phase 1b clinical study - TipRanks
Revelation Biosciences Doses First Patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients - Business Wire
Artificial Intelligence (AI) News Live Feed - StockTitan
Revelation Biosciences gets continued listing approval from Nasdaq - MSN
Revelation Biosciences Says Regained Compliance With Nasdaq Minimum Bid Price Requirement - MarketScreener
Revelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval - Business Wire
Can This Biotech's New Kidney Disease Trial Transform CKD Treatment? Key Details - Stock Titan
Larchmont broker accused of years-long insider trading scheme - Westfair Online
Allergic Rhinitis Market Expected to rise, 2034 | Regeneron, - openPR
Pre-market Movers: SLGL, VIRX, ANVS, CUTR... - RTTNews
Neumora Therapeutics, Rain Oncology, and Carmell Corporation: Stock Volatility Highlights Major Market Moves - HPBL
Allergic Rhinitis Market to Show Remarkable Growth Trends from - openPR
Revelation Biosciences stock hits 52-week low at $0.28 - MSN
REVB Start 1B Trial and Announces Split - MSN
REVB: Phase 1b Begins and Nasdaq Compliance Regained - Research Tree
Stock market news: MiNK Therapeutics -93.51%, Revelation Biosciences -93.45% among biggest losers during mid day trading - Business Upturn
Stock market news: Vincerx Pharma plunged by 95.86% while MiNK Therapeutics was down by 94.26% during mid day trading - Business Upturn
Stock market today: Revelation Biosciences -93.16%, MiNK Therapeutics -91.40% among biggest losers in early trading - Business Upturn
Stock market today: Vincerx Pharma declined by 95.75% whereas Revelation Biosciences - Business Upturn
Revelation Biosciences Inc (REVB) Has Strong Growth Prospects Through 2025 - Marketing Sentinel
Anthem man charged with insider trading - Foothills Focus
Revelation Biosciences stock hits 52-week low at $0.28 By Investing.com - Investing.com Canada
Revelation Biosciences Inc. Announces 1-for-16 Reverse Stock Split Effective January 28, 2025 - BioSpace
Revelation Biosciences to effect 1-for-16 reverse stock split to regain Nasdaq compliance - MSN
Revelation Biosciences Starts its PRIME Phase 1b Clinical Study of Gemini in CKD Patients - Marketscreener.com
Revelation Bio Launches Phase 1b Trial of Gemini for Advanced Chronic Kidney Disease Treatment - Stock Titan
Florida Trader Among 4 Arrested for 7-Year-Long Insider Trading Scheme - NewsBreak
Revelation Biosciences (REVB) Price Target Increased by 242.79% to 40.04 - MSN
Broker, Traders Charged With $1M Insider Trading Scheme - Law360
Personal Finance - Business Wire
Several More Companies Propose Move From Delaware To Nevada - JD Supra
Revelation Biosciences Inc (REVB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.00%
자본화:
|
볼륨(24시간):